MedKoo product information:

GPX150

GPX-150 is a synthetic non-cardiotoxic analogue of the anthracycline antibiotic doxorubicin with potential antineoplastic activity. Anthracycline analogue GPX-150 intercalates DNA and impedes the activity of topoisomerase II, inducing single and double-stranded breaks in DNA; inhibiting DNA replication and/or repair, transcription, and protein synthesis; and activating tumor cell apoptosis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

As of August 2010, GPX-150 is under Phase I clinical trials sponsored by Coronado Biosciences, Inc. This is a Phase 1 safety and dose escalation study to define the maximum tolerated dose (MTD) and identify the dose limiting toxicities (DLT) following IV administration of GPX-150 once every 3 weeks. Escalating doses starting at the dose of 14 mg/m2 and increasing to the dose of 265 mg/m2 will be administered IV once every 3 weeks for up to 8 cycles of treatment. Patients who have previously received an anthracycline are limited to 4 cycles of treatment. (source: http://clinicaltrials.gov/ct2/show/NCT00710125).

Current developer:  Gem Pharmaceuticals, Inc and ACCESS Oncology, Inc.

1. Zhang; Xini (Hoover, AL), Olson; Richard D. (Nampa, ID) 5-imino-13-deoxy anthracycline derivatives, their uses, and processes for preparing them, United States Patent 5942605.